StockData
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. (OKUR) stock

OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$2.58−0.17 (-6.18%)

Close on Nov 17, 2026Market cap $104.48MP/E –Yield –

OnKure Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

OnKure Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$47.84M. For fiscal 2025 it was -$51.83M. The highest annual figure on record is -$18.54M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$51.83M–
FY2024Dec 31, 2024-$51.12M–
FY2023Dec 31, 2023-$34.55M–
FY2022Dec 31, 2022-$47.36M–
FY2021Dec 31, 2021-$37.98M–
FY2020Dec 31, 2020-$18.54M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.35M–
Q1 FY2026Mar 31, 2026-$12.94M–
Q4 FY2025Dec 31, 2025-$11.51M–
Q3 FY2025Sep 30, 2025-$13.04M–
Q2 FY2025Jun 30, 2025-$13.27M–
Q1 FY2025Mar 31, 2025-$14.01M–
Q4 FY2024Dec 31, 2024-$23.35M-348.9%
Q3 FY2024Sep 30, 2024-$10.66M–
Q2 FY2024Jun 30, 2024-$6.47M–
Q1 FY2024Mar 31, 2024-$10.63M–
Q4 FY2023Dec 31, 2023$9.38M–
Q3 FY2023Sep 30, 2023-$18.77M–
Q2 FY2023Jun 30, 2023-$16.11M–
Q1 FY2023Mar 31, 2023-$9.05M–
Q4 FY2022Dec 31, 2022-$15.61M–
Q3 FY2022Sep 30, 2022-$10.79M–
Q2 FY2022Jun 30, 2022-$11.96M–
Q1 FY2022Mar 31, 2022-$9.00M–
Q4 FY2021Dec 31, 2021-$10.02M–
Q3 FY2021Sep 30, 2021-$9.67M–
Q2 FY2021Jun 30, 2021-$9.70M–
Q1 FY2021Mar 31, 2021-$8.59M–
Q4 FY2020Dec 31, 2020-$5.41M–
Q3 FY2020Sep 30, 2020-$5.74M–
Q2 FY2020Jun 30, 2020-$2.94M–
Q1 FY2020Mar 31, 2020-$4.45M–

More OnKure Therapeutics figures

See a number that looks wrong?